IDENTIFICATION OF CLINICAL AND NEUROLOGICAL SYMPTOMS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS
Abstract
References
1. American Diabetes Association. (2023). Standards of Medical Care in Diabetes—2023. Diabetes Care, 46(Supplement_1), S1–S284.
2. Feldman, E. L., Nave, K. A., Jensen, T. S., & Bennett, D. L. (2019). New Horizons in Diabetic Neuropathy: Mechanisms, Bioenergetics, and Pain. Neuron, 101(6), 987–1000.
3. Tesfaye, S., Boulton, A. J. M., Dyck, P. J., Freeman, R., Horowitz, M., Kempler, P., Lauria, G., Malik, R. A., Spallone, V., Vinik, A., & Bernardi, L. (2010). Diabetic Neuropathies: Update on Definitions, Diagnostic Criteria, Estimation of Severity, and Treatments. Diabetes Care, 33(10), 2285–2293.
4. Callaghan, B. C., Cheng, H. T., Stables, C. L., Smith, A. L., & Feldman, E. L. (2012). Diabetic Neuropathy: Clinical Manifestations and Current Treatments. The Lancet Neurology, 11(6), 521–534.
5. Pop-Busui, R., Boulton, A. J., Feldman, E. L., Bril, V., Freeman, R., Malik, R. A., Sosenko, J. M., & Ziegler, D. (2017). Diabetic Neuropathy: A Position Statement by the American Diabetes Association. Diabetes Care, 40(1), 136–154.
